PT-141, commonly called bremelanotide, should be obtained through a licensed clinician who can review your symptoms, health history, medicines, and goals. Chia offers compounded PT-141 nasal spray after online clinician review when appropriate; a prescription is not guaranteed, and clinical research on bremelanotide does not establish identical outcomes for a compounded nasal formulation.
Wondering if PT-141 is right for you? Take the 3-min clinical quiz.
See if you qualify →What is the safest way to get PT-141 nasal spray?
The safest path is a licensed clinician evaluation followed, when clinically appropriate, by prescription dispensing from a licensed pharmacy. That process creates room to discuss the symptom itself, medical history, current medicines, possible risks, and whether PT-141 fits the situation.
Why clinician evaluation matters before obtaining a peptide medication
Sexual desire and arousal concerns can have physical, emotional, relationship, hormonal, and medication-related contributors. The bremelanotide trials enrolled defined groups of premenopausal women with hypoactive sexual desire disorder or female sexual arousal disorder; trial findings should not be assumed to apply to every concern involving libido or arousal. 2 6
What legitimate prescription access should include
Look for a clinician who reviews your health information, a pharmacy that dispenses a prescription, clear formulation details, and a way to ask follow-up questions. Our guide to getting a peptide prescription safely explains why a prescription and pharmacy source matter more than a seller's marketing language.
Why research-use-only sellers and marketplace listings require caution
A “research use only” label is not a substitute for a prescription or medical oversight. It also does not tell you whether a product is appropriate for personal use, whether its formulation matches a studied product, or how to manage side effects. For more on evaluating online listings, read our guide to buying PT-141 online safely and our review of PT-141 marketplace listings.
What should I know about PT-141 before seeking it?
PT-141 and bremelanotide refer to the same active compound in common clinical discussion. Bremelanotide is a melanocortin receptor agonist, meaning it acts on melanocortin signaling pathways rather than working like a hormone replacement medicine or a PDE5 medication. 2
PT-141, bremelanotide, and the Vyleesi brand name
Bremelanotide is the name used in the published clinical-trial literature. Vyleesi is a brand name associated with bremelanotide. When comparing information online, check whether a source is discussing a studied bremelanotide product, a brand product, or a compounded formulation; those are not interchangeable categories. 1 3
What a compounded nasal formulation is and is not
A compounded formulation is prepared by a compounding pharmacy pursuant to a prescription. It is not the same thing as the specific products studied in the phase 2 and phase 3 bremelanotide trials. Those studies cannot establish equivalent absorption, safety, dosing, or effectiveness for compounded PT-141 nasal spray. 2 3
What happens during an online PT-141 prescription evaluation?
An online evaluation gathers the information a clinician needs to decide whether a prescription evaluation is appropriate. It is not an automatic approval process, and it should not replace urgent or in-person care when that is needed.
Health history, symptoms, current medicines, and treatment goals
A clinician may review your symptoms, relevant health history, current medications, prior treatments, and treatment goals. This matters because the people enrolled in bremelanotide research were selected using study criteria, not simply because they reported a general concern about desire or arousal. 2 6
Why eligibility and a prescription cannot be guaranteed
A licensed provider must decide whether prescribing is clinically appropriate after reviewing the available information. A clinician may determine that PT-141 is not a fit, that more evaluation is needed, or that a different care approach better matches the concern.
When a clinician may recommend another evaluation or treatment approach
The phase 3 RECONNECT trials focused on premenopausal women with hypoactive sexual desire disorder, so they do not answer every question about sexual health or every patient population. 3 If symptoms are new, severe, distressing, or connected with other health changes, a clinician can help determine the right next step.
What does research say about bremelanotide?
Human research on bremelanotide includes a phase 2 randomized, placebo-controlled trial with 612 enrolled participants and two completed phase 3 trials with 723 and 714 enrolled participants. 2 6 7 8 These trials studied defined premenopausal populations, not compounded nasal PT-141.
What human randomized trials studied
The phase 2 trial enrolled premenopausal women with female sexual arousal disorder and/or hypoactive sexual desire disorder. 2 6 The RECONNECT phase 3 trials evaluated bremelanotide in premenopausal women with hypoactive sexual desire disorder and reported outcomes for the studied treatment products. 3 Individual results vary.
Who was represented in the phase 2 and phase 3 research
The registered phase 2 study enrolled 612 participants, while the two phase 3 studies enrolled 723 and 714 participants. 6 7 8 This is useful context, but it also sets a limit: evidence from these trials should not be generalized automatically to people outside the studied populations.
What safety findings mean for a compounded nasal formulation
The clinical-development safety analysis and phase 3 trial report describe tolerability and adverse-event findings for their studied bremelanotide products. Nausea was a commonly reported adverse event, and the research also evaluated events such as flushing, headache, and blood-pressure changes. 1 3 These data are informative for a clinician conversation, but they do not prove matching safety or effectiveness for compounded PT-141 nasal spray.
3-min quiz
Considering a clinician-reviewed PT-141 option?
Chia offers compounded PT-141 nasal spray after a licensed US provider reviews your health questionnaire. A prescription requires a medical evaluation and is not guaranteed. The medication is compounded by a US state-licensed 503A pharmacy; compounded medications are not FDA-approved.
What safety questions should I discuss before using PT-141?
A good visit should cover your medical history and current medicines before any prescribing decision. Trial safety findings are a starting point for that discussion, not a self-treatment plan. 1 3
Potential adverse effects and tolerability findings from clinical development
In the bremelanotide clinical-development program, reported adverse effects included nausea, flushing, and headache, among others. 1 The phase 3 trials also evaluated safety and tolerability alongside efficacy outcomes. 3 Tell the prescriber about prior medication reactions and any symptoms that concern you.
Medical history, cardiovascular considerations, and medication review
Because the clinical program assessed blood-pressure-related findings, cardiovascular history is one of the topics that belongs in a prescriber conversation. 1 A complete medication review also helps the clinician decide whether treatment, more evaluation, or another approach makes sense.
Why individualized instructions belong with the prescriber
Do not use online dose charts, marketplace instructions, or another person's regimen as a substitute for care. A prescriber who knows the formulation and your health history should make treatment and adjustment decisions; our overview of PT-141 evidence and safety covers the same distinction in more detail.
How does PT-141 nasal spray at Chia work?
At Chia, PT-141 nasal spray plans currently start at $159 per month and begin with an online health questionnaire. A licensed US provider reviews the information and prescribes only when clinically appropriate; eligibility and a prescription are never guaranteed.
When prescribed, PT-141 is compounded in the US by a state-licensed 503A compounding pharmacy and shipped to the patient's door. Patients can message their care team through the portal between visits, and providers guide treatment decisions over time. Our PT-141 option is nasal spray; we do not present it as a replacement for an individualized sexual-health assessment.
| Chia option | What it includes | Current starting price | Important context |
|---|---|---|---|
| PT-141 nasal spray | Compounded PT-141 nasal spray after clinician review | From $159/mo | Prescription only when clinically appropriate; provider-guided decisions. |
| Spark protocol | PT-141 nasal spray | From $159/mo | A clinician can help assess whether this option fits the patient's goals and history. |
The Spark protocol includes PT-141 nasal spray. The right question is not whether an option is available online, but whether a licensed clinician believes it is appropriate for your specific health picture.
How should I compare PT-141 access options?
Compare access routes by clinical oversight and pharmacy accountability, not only convenience or price. A legitimate option makes it possible to ask questions before treatment and seek support afterward.
| Access route | Clinical review | Prescription pharmacy dispensing | Follow-up opportunity | What to clarify |
|---|---|---|---|---|
| Licensed telehealth clinic | Online health review by a licensed clinician before a prescribing decision | Yes, when prescribed | Usually through a patient portal or clinic process | Provider licensure, pharmacy, formulation, total cost, and follow-up. |
| In-person clinician | Office-based assessment before a prescribing decision | Yes, when prescribed | Office or practice follow-up | Whether the clinician addresses sexual-health concerns and medication review. |
| Unverified online seller or research listing | No patient-specific medical evaluation | Not a patient prescription pathway | No established clinical follow-up | Avoid treating a research label or marketing claim as medical guidance. |
A useful question to ask any clinic is who will review your information, who compounds or dispenses the prescription, and how you can contact the care team if questions arise. A lower listed price does not answer those care and accountability questions.
What should I do next if I am considering PT-141?
Start by preparing a short list of health questions for a licensed clinician. Include your symptoms, goals, relevant health history, medicines, past treatments, and concerns about side effects or formulation.
- Ask whether your symptoms need additional evaluation before medication is considered.
- Ask what evidence applies to the specific formulation being discussed.
- Ask how the prescriber will review safety concerns and provide follow-up.
- Use a clinician-reviewed process rather than self-prescribing from a research-use-only listing.
PT-141 access should begin with a licensed clinician who can determine whether prescription treatment is clinically appropriate. A research-use-only listing is not a substitute for a patient prescription or medical oversight.
PT-141 is commonly used to refer to bremelanotide. Vyleesi is a brand name associated with bremelanotide. It is important to distinguish studied or brand products from compounded formulations.
No direct equivalence should be assumed. The available trials studied specific bremelanotide products in defined populations, so they do not establish the same outcomes, absorption, safety, or effectiveness for compounded nasal PT-141.
A licensed telehealth clinician may determine whether prescribing is appropriate after reviewing a patient's health information. Eligibility and a prescription are never guaranteed.
Do not treat that label as permission or guidance for personal use. Consider a licensed clinician and prescription pharmacy instead, so your health history, medicines, formulation, and follow-up can be addressed.
Ask about nausea, flushing, headache, blood-pressure-related considerations, medication interactions, and any risks that may be relevant to your health history. Your prescriber should provide individualized safety guidance.
3-min quiz
Start with a clinician-reviewed evaluation
If you are considering PT-141 nasal spray, Chia's online process lets a licensed US provider review your health information and goals. A medical evaluation is required, and a prescription is not guaranteed. Chia's medication is compounded through US state-licensed 503A pharmacies and shipped to your door; compounded medications are not FDA-approved.
References
- 1.Clayton AH, Kingsberg SA, Portman D, et al. Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of Women's Health. 2022.
- 2.Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's Health. 2016.
- 3.Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019.
- 4.Simon JA, Kingsberg SA, Portman D, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of Women's Health. 2022.
- 5.Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. The Journal of Urology. 2008.
- 6.ClinicalTrials.gov. Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder (NCT01382719). 2026.
- 7.ClinicalTrials.gov. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (NCT02333071). 2026.
- 8.ClinicalTrials.gov. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (NCT02338960). 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if PT-141 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
